Amgen (AMGN) Liabilities and Shareholders Equity (2016 - 2025)
Amgen (AMGN) has 17 years of Liabilities and Shareholders Equity data on record, last reported at $90.6 billion in Q4 2025.
- For Q4 2025, Liabilities and Shareholders Equity fell 1.36% year-over-year to $90.6 billion; the TTM value through Dec 2025 reached $358.0 billion, down 2.35%, while the annual FY2025 figure was $90.6 billion, 1.36% down from the prior year.
- Liabilities and Shareholders Equity reached $90.6 billion in Q4 2025 per AMGN's latest filing, roughly flat from $90.1 billion in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $97.2 billion in Q4 2023 and bottomed at $59.2 billion in Q1 2022.
- Average Liabilities and Shareholders Equity over 5 years is $79.4 billion, with a median of $89.0 billion recorded in 2023.
- Peak YoY movement for Liabilities and Shareholders Equity: decreased 8.06% in 2021, then soared 52.24% in 2023.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $61.2 billion in 2021, then increased by 6.47% to $65.1 billion in 2022, then surged by 49.19% to $97.2 billion in 2023, then decreased by 5.47% to $91.8 billion in 2024, then fell by 1.36% to $90.6 billion in 2025.
- Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $90.6 billion in Q4 2025, $90.1 billion in Q3 2025, and $87.9 billion in Q2 2025.